Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.5 USD | +0.32% | -1.14% | +100.85% |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Drug Retailers
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+100.85% | 681M | - | ||
+17.55% | 3.03B | D+ | ||
+15.99% | 1.72B | - | ||
+45.54% | 180M | - | ||
-4.48% | 99.66M | - | ||
+0.97% | 97.37M | - | - | |
+56.25% | 71.9M | - | C | |
+44.94% | 54.13M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
- Stock Market
- Equities
- GLASF Stock
- Ratings Glass House Brands Inc.